Related Experiment Video
Updated: Aug 20, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Yufang Shao1, Zhonghua Gao, Paul A Marks
1Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
Histone deacetylase (HDAC) inhibitors can induce programmed cell death in cancer cells, although the underlying mechanism is obscure. In this study, we show that two distinct HDAC inhibitors, butyrate and suberoylanilide hydroxamic acid (SAHA), induced caspase-3 activation and cell death in multiple human cancer cell lines. The activation of caspase-3 was via the mitochondria/cytochrome c-mediated apoptotic pathway because it was abrogated in mouse embryonic fibroblasts with knockout of Apaf-1, the essential mediator of the pathway. Overexpression of Bcl-XL in HeLa cells also blocked caspase activation by the HDAC inhibitors. Nevertheless, Apaf-1 knockout, overexpression of Bcl-XL, and pharmacological inhibition of caspase activity did not prevent SAHA and butyrate-induced cell death. The cells undergoing such caspase-independent death had unambiguous morphological features of autophagic cell death. Therefore, HDAC inhibitors can induce both mitochondria-mediated apoptosis and caspase-independent autophagic cell death. Induction of autophagic cell death by HDAC inhibitors has clear clinical implications in treating cancers with apoptotic defects.
Insights
Histone deacetylase (HDAC) inhibitors trigger cancer cell death through apoptosis and a distinct form of programmed cell death called autophagy. This dual mechanism offers new therapeutic strategies for cancers with defects in apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Histone deacetylase (HDAC) inhibitors are known to induce cancer cell death.
- The precise mechanisms by which HDAC inhibitors trigger cell death remain incompletely understood.
- Understanding these pathways is crucial for optimizing cancer therapy.
Purpose of the Study:
- To elucidate the mechanisms of cell death induced by HDAC inhibitors in human cancer cells.
- To investigate the roles of apoptosis and autophagy in HDAC inhibitor-mediated cell death.
- To explore the clinical implications of these findings for cancer treatment.
Main Methods:
- Treatment of human cancer cell lines with HDAC inhibitors (butyrate and SAHA).
- Assessment of caspase-3 activation and apoptotic pathway involvement (using Apaf-1 knockout and Bcl-XL overexpression).
- Morphological analysis to identify autophagic cell death features.
Main Results:
- HDAC inhibitors induced caspase-3 activation via the mitochondria/cytochrome c pathway.
- Apaf-1 knockout and Bcl-XL overexpression partially inhibited apoptosis but not overall cell death.
- Cells exhibited morphological characteristics of autophagic cell death, independent of caspase activation.
Conclusions:
- HDAC inhibitors can induce both apoptosis and caspase-independent autophagic cell death.
- Autophagic cell death induction by HDAC inhibitors presents a promising therapeutic avenue for cancers with apoptotic defects.
- These findings highlight the complex interplay of cell death pathways in response to HDAC inhibition.
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
Apoptosis
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Cellular Injury V: Apoptosis and Autophagy
The Extrinsic Apoptotic Pathway
Cellular Injury IlI: Cellular Death

